Conference Speakers
Cultural Speakers
Cultural practices, beliefs, and norms play a very important role not only in delivering health care to clients and patients, but also in how that health care is received and what outcomes are possible. Diversity within those beliefs and practices, and as a result of available resources or social economic/demographic circumstances, must be fully understood in order for health care professionals to provide the best care possible no matter where they are in the world, or what culture they are practicing within.
At GOLD Perinatal Care, we understand the importance of Culture and Diversity in health care, and we are working hard to bring you speakers and presentations from around the world that will help you understand the patients and clients you are working with. Discovering how health care is provided and received in other countries and cultures around the world can have a positive impact on our own professional practice. Given that culture is defined by much more than political borders, GOLD Perinatal Care invites speakers to share their knowledge and expertise about perinatal health care from a geographically-based focus or a people-group focus from within a particular set of beliefs, lifestyle or minority. This year, our Culture and Diversity speakers will be presenting on:
X
Dr. Speakers Full Name
Speaker Credentials
Annet Mulder first became interested in breastfeeding in the year 2000, when she became a mother for the first time. During and because of her own breastfeeding experiences, in 2002 she became a volunteer with the Dutch breastfeeding Organization and in 2008 sat for and passed the exam administered by the International Board of Lactation Consultant Examiners. As an International Board Certified Lactation Consultant, she now
Annet Mulder first became interested in breastfeeding in the year 2000, when she became a mother for the first time. During and because of her own breastfeeding experiences, in 2002 she became a volunteer with the Dutch breastfeeding Organization text text text text more name mulder first became interested in breastfeeding in the year 2000, when she became.
X
Abstract: Breastfeeding mothers may turn to formula and/or bottles for many
reasons. Some supplementing with formula by bottle when they reach out for help, and for some moms,
supplementing by alternative methods may be very overwhelming. Some moms need or choose a combination
of breast milk and formula and others may decide to give occasional or regular bottles of expressed
milk. Whatever the reason, as health care professionals helping a mother to breastfeed, it is our
job to be able to help her to reach her own personal goals even when she needs, or chooses to use,
bottles or formula. Learn about baby-led bottle feeding and why it's so important, different types
of formula, their uses and how to prepare them, and how this all fits in with the WHO code and our
code of professional conduct.
View Full Presentation Information & Scheduling
Dr. Speakers Full Name
Speaker Credentials
Speakers (5191)
Head, Thoracic and H&N cancer Therapeutics CTEP/NCI. worked at the FDA prior to joining NCI and served as Chief Center for Thoracic oncology at Georgetown Hospital for 7 years
Published in
Speakers
Jia Luo, MD, is a fellow in the Thoracic Oncology Service at Memorial Sloan Kettering Cancer Center. Dr. Luo received her medical degree at Stanford School of Medicine and completed residency and a chief residency year at Oregon Health & Science University. She is currently supported by an awarded Investigational Cancer Therapeutics T32 grant, and her work has been focused on developing tools to understand response to immunotherapy. She has first and co-authored papers in Cancer Discovery, Annals of Oncology, Nature Reviews Clinical Oncology, Clinical Cancer Research, and JCO: Precision Oncology. She developed an IIT at the AACR/ ASCO Methods in Clinical Cancer Research Workshop, and the work was supported by a Young Investigator Award from the Conquer Cancer Foundation of ASCO.
Published in
Speakers
Christine M. Lovly, MD, PhD is currently an Associate Professor of Medicine at the Vanderbilt Ingram Cancer Center. Her laboratory research is directed at understanding and developing improved therapeutic strategies for specific clinically relevant molecular subsets of cancer. Dr. Lovly has received grant funding from NIH/NCI, the American Cancer Society, the Damon Runyon foundation, the LUNGevity foundation, the GO2 foundation, the V Foundation, AACR, and LCFA/IASCL. She is an active member of ASCO, AACR, and IASLC. She is also an elected member of the American Society for Clinical Investigation (ASCI) and serves on the Editorial Board for Cancer Discovery. Dr. Lovly is also an invited member of the Scientific Leadership Boards for the GO2 Foundation for Lung Cancer research, the LUNGevity foundation, and the Lung Cancer Research Foundation.
Published in
Speakers
Stephen V. Liu is an Associate Professor and the Director of Thoracic Oncology at Georgetown University and the Head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center.
Published in
Speakers
Aaron E. Lisberg, MD, is a medical oncologist with an emphasis on clinical and translational research in thoracic oncology at the David Geffen School of Medicine at UCLA. He conducts translational research aimed at identifying novel therapeutic approaches for the treatment of thoracic malignancies, with a specific focus on immune-based, cellular, and metabolically targeted therapies and has published extensively.
Published in
Speakers
Dr. Jessica Lin is a medical oncologist specializing in the care of patients with thoracic
malignancies. Dr. Lin received her MD from Harvard Medical School. After completing her residency in internal medicine at the Brigham and Women’s Hospital and fellowship in medical oncology at the Dana-Farber/Partners CancerCare program, she joined the faculty at Massachusetts General Hospital Cancer Center and Harvard Medical School.
The primary focus of Dr. Lin’s research is to develop novel therapeutic and biomarker strategies for patients with advanced lung cancers. Her translational research efforts are dedicated to the study of resistance mechanisms and exceptional responses to targeted therapies in molecularly defined subsets of lung cancer. Dr. Lin is a member of the International Association for the Study of Lung Cancer, American Association for Cancer Research, and American Society of Clinical Oncology.
Published in
Speakers
Bob Li, MD, PhD, MPH, FRACP, is an Australian medical oncologist and physician-scientist at Memorial Sloan Kettering Cancer Center, New York, who specializes in early-phase drug development for lung cancers and solid tumors. He is Chief Scientific Officer, MSK Direct, responsible for scientific innovation in MSK’s digital outreach strategy. He is also Co-Director of MSK’s multidisciplinary Thoracic Liquid Biopsy Program which is dedicated to developing the latest biotechnology on circulating biomarkers to transform the care of patients. As MSK’s Physician Ambassador to China and Asia-Pacific, Dr. Li provides administrative leadership in international patient care, research and education programs to advance MSK’s mission abroad with transparency and impact. Through compassionate care and international collaboration, his career is dedicated to winning the global war on cancer and bringing real hope to patients.
Published in
Speakers
Dr. Levy is Associate Professor at the Johns Hopkins School of Medicine and recently recruited to be Clinical Director of The Sidney Kimmel Cancer Center, Johns Hopkins Medicine at Sibley Hospital in Washington DCDr Levy is a physician scientist who is currently leading global immunotherapy trials. In addition, he currently leads multiple targeted therapy trial with specific interest in EGFR mutations. Dr. Levy has played an integral role on several American Society of Clinical Oncology (ASCO) committees and currently serves as editor in chief for the ASCO Self Evaluation Program (SEP). He also serves on the Lungevity Scientific Advisory board as well as the IASLC’s International Lung Cancer Foundation Advisory Board. He is an ad hoc reviewer for Clinical Cancer Research (CCR), Annals of Oncology and the Journal of Clinical Oncology. He was selected as one of only 15 oncologist in the country to the prestigious ASCO Leadership Development Program whose mission is to identify and develop future leaders of ASCODr. Levy is Associate Professor at the Johns Hopkins School of Medicine and recently recruited to be Clinical Director of The Sidney Kimmel Cancer Center, Johns Hopkins Medicine at Sibley Hospital in Washington DCDr Levy is a physician scientist who is currently leading global immunotherapy trials. In addition, he currently leads multiple targeted therapy trial with specific interest in EGFR mutations. Dr. Levy has played an integral role on several American Society of Clinical Oncology (ASCO) committees and currently serves as editor in chief for the ASCO Self Evaluation Program (SEP). He also serves on the Lungevity Scientific Advisory board as well as the IASLC’s International Lung Cancer Foundation Advisory Board. He is an ad hoc reviewer for Clinical Cancer Research (CCR), Annals of Oncology and the Journal of Clinical Oncology. He was selected as one of only 15 oncologist in the country to the prestigious ASCO Leadership Development Program whose mission is to identify and develop future leaders of ASCO.
Published in
Speakers
Dr Natasha Leighl leads the Thoracic Medical Oncology Group at the Princess Margaret Cancer Centre, and is Professor in the Department of Medicine, and Adjunct Professor in the Institute of Health Policy, Management and Evaluation at the University of Toronto. She holds the OSI Pharmaceuticals Foundation Chair in Cancer New Drug Development through the Princess Margaret Cancer Foundation. She has published more than 300 peer-reviewed papers, has held (as principal or co-investigator) over $600 million in peer-reviewed grant funding, and has mentored many oncology trainees that have gone on to leadership roles in oncology around the world. Recently, she was awarded the American Society of Clinical Oncology Excellence in Teaching Award (2019). After receiving her MD from the University of Toronto, Canada, Dr. Leighl completed residencies in internal medicine at the University of Calgary and in medical oncology at the University of Toronto. She subsequently completed a Fellowship in Thoracic Oncology with Dr. Frances Shepherd at the Princess Margaret Hospital in Canada, a Fellowship in Clinical Oncology with Prof. Martin Tattersall at the University of Sydney in Australia, and received her Masters in Medical Science (MMSc) in Clinical Epidemiology at the University of Newcastle, Australia.
Dr Leighl’s main interest is in developing new treatments in lung cancer and improving lung cancer diagnostics. She is involved in clinical studies of novel agents for the treatment of thoracic cancers, has led several international and cooperative group studies in lung cancer and has served as a member of the Lung Disease Site Group Executive of the Canadian Cancer Clinical Trials Group. She was Co-Chair of the CCTG Committee on Economic Analysis, Congress Co-President of the 2018 World Conference in Lung Cancer, and serves on multiple committees including the ASCO Thoracic Guidelines Advisory Group, is co-section editor of The Oncologist and Current Oncology, an editorial board member of the Journal of Thoracic Oncology, British Journal of Cancer, and is a member of the IASLC Quality and Value Committee. Previously she served as Web Editor of the Journal of Thoracic Oncology, on the editorial board of the Journal of Clinical Oncology, the Royal College of Physicians & Surgeons of Canada Medical Oncology Examination Board and more. She also served as President of Lung Cancer Canada from 2009 to 2016, and serves on the Scientific Advisory Board of the Lung Cancer Foundation of America, and was recently elected to the Board of Directors of the Americas Health Foundation.
Dr Leighl’s main interest is in developing new treatments in lung cancer and improving lung cancer diagnostics. She is involved in clinical studies of novel agents for the treatment of thoracic cancers, has led several international and cooperative group studies in lung cancer and has served as a member of the Lung Disease Site Group Executive of the Canadian Cancer Clinical Trials Group. She was Co-Chair of the CCTG Committee on Economic Analysis, Congress Co-President of the 2018 World Conference in Lung Cancer, and serves on multiple committees including the ASCO Thoracic Guidelines Advisory Group, is co-section editor of The Oncologist and Current Oncology, an editorial board member of the Journal of Thoracic Oncology, British Journal of Cancer, and is a member of the IASLC Quality and Value Committee. Previously she served as Web Editor of the Journal of Thoracic Oncology, on the editorial board of the Journal of Clinical Oncology, the Royal College of Physicians & Surgeons of Canada Medical Oncology Examination Board and more. She also served as President of Lung Cancer Canada from 2009 to 2016, and serves on the Scientific Advisory Board of the Lung Cancer Foundation of America, and was recently elected to the Board of Directors of the Americas Health Foundation.
Published in
Speakers
Dr. Jonathan Lehman is a practicing medical thoracic oncologist at Vanderbilt University Medical Center and the Department of Veterans Affairs in Nashville, TN. Dr. Lehman’s current research focuses on small cell lung carcinoma (SCLC), the most aggressive subtype of lung cancer, and is driven by his clinical experience with Veterans who are disproportionately afflicted by the disease. SCLC is particularly devastating because most tumors develop metastatic recurrence despite initial response to therapeutic intervention. Dr. Lehman’s research focuses on rare chemotherapy resistant subpopulations and he has described distinct neuroendocrine survival signaling in SCLC and rare chemotherapy stable subpopulations encovered by a novel single cell mass cytometry panel that can identify the expression of more than 40 individual proteins to cluster subpopulations of cells within a large number of tumor cells. He is delighted to participate in the Vanderbilt University U54 group focused on characterizing and modeling different subpopulations in Small Cell Lung Cancer. He is grateful to the NCI, VA, and Department of Defense for continued funding support and his collaborators in the Rudin, Massion, and ECOG and U54 labs.
Published in
Speakers
